LOS GATOS, Calif., Nov. 26 /PRNewswire/ -- TriCipher, the experts in strong authentication, today announced that its MySignatureBook digital signing solution has been certified as compliant with the SAFE-BioPharma(TM) digital identity and signature standard.
MySignatureBook 1.1 is an online digital signature workflow solution that manages the collection and application of digital signatures to PDF documents using Adobe Reader. The ability to leverage SAFE-BioPharma credentials for signing allows MySignatureBook to manage the signature process for many regulated and highly sensitive documents that are incredibly common to the life sciences industry.
"Digital signatures that meet the SAFE-BioPharma digital standard are accepted by the FDA and meet legal signature standards across the EU and the European Economic Area," said Mollie Shields-Uehling, president and CEO, SAFE-BioPharma Association. "Compliance with the SAFE-BioPharma standard means our members and TriCipher customers can have confidence in MySignatureBook when it is used with SAFE-BioPharma credentials."
MySignatureBook 1.1, announced today, is the second major enhancement of the online digital signing solution and is already deployed across several companies in the pharmaceutical and healthcare industries. New features include a truly zero-footprint client option and the ability to sign and manage groups of documents for companies with high-volume signature requirements.
"We have worked closely with our major customers in the life sciences industry to develop the features in MySignatureBook 1.1," said John De Santis, president and CEO of TriCipher. "Certification with the SAFE-BioPharma standard underlines our commitment to industry standards and supporting the pharmaceutical and healthcare communities."
TriCipher and SAFE-BioPharam will host a joint webcast on December 16th on digital signatures in the pharmaceutical and health care industries. Visit http://www.tricipher.com/digital-signatures/ to register for this event.
TriCipher, Inc. provides a unified authentication infrastructure to protect web and enterprise portals, the people that use them and the business process that flows through them against fraud and identity theft. The TriCipher Armored Credential System(TM) (TACS) is the first authentication system that enables companies to deploy and manage multiple types of credentials from a single infrastructure. Through this flexible "Authentication Ladder," TriCipher protects customer investment by adjusting authentication strength to defeat new threats and to meet regulatory changes without the need to implement a new infrastructure. Recently, TriCipher introduced myOneLogin(TM) the first secure on-demand offering that delivers strong authentication, single sign-on (SSO) convenience and the ability to seamlessly integrate multiple Software as a Service (SaaS) applications in a single solution. Founded in 2000, TriCipher is headquartered in Los Gatos, Calif. The company is funded by ArrowPath Venture Capital, EPIC Ventures, Intel Capital, RBC Technology Ventures, and Trident Capital. For more information, visit TriCipher on the web at http://www.tricipher.com.
TriCipher mySignatureBook(TM) is a web-based digital signing solution that gathers multiple signatures from a centrally managed, Web-based workflow to a single, unaltered document. mySignatureBook ensures end-to-end security for highly regulated and sensitive documents, and eliminates time-consuming and costly paper-based signature processes, including shipping and storage. mySignaureBook supports a range of MSB supports a variety of strong credentials, including TriCipher clientless credentials, SAFE(TM) credentials, TriCipher ID Tool and ID Tool ToGo and any PKCS#11 digital credential. A robust web services interface makes it easy to integrate MSB with a variety of applications and document management systems.
SAFE-BioPharma Association is the non-profit association that created and manages the SAFE-BioPharma(TM) digital identity and signature standard for the pharmaceutical and healthcare industries. The SAFE-BioPharma industry standard is used to mitigate legal, regulatory and other business risk associated with business-to-business and business-to-regulator electronic transactions. It facilitates interoperability by providing a secure, enforceable, and regulatory-compliant way to verify identities of parties involved in electronic transactions. SAFE-BioPharma's vision is to be a catalyst in transforming the biopharmaceutical and healthcare communities to a fully electronic business environment by 2012. The Association's members include Amgen, AstraZeneca, Bristol-Myers Squibb, Genzyme, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, Procter & Gamble, Roche and Sanofi-Aventis. For more information, http://www.safe-biopharma.org.
All product and company names herein may be trademarks of their registered owners.
|SOURCE TriCipher, Inc.|
Copyright©2008 PR Newswire.
All rights reserved